The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.
暂无分享，去创建一个
S. Dawson | M. Dawson | C. Pott | A. Roberts | C. Tam | R. Hicks | M. Dreyling | J. Seymour | M. Anderson | D. Westerman | S. Kamel | Glenda Burke | Sarah Kamel